CYT insider filings
Cyteir Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-03-25. Screen CYT transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for CYT between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Cyteir Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-03-25 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 170,589 @ $2.95 | EDGAR |
| 2024-03-19 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 113,777 @ $3.01 | EDGAR |
| 2024-03-05 | 4 | Gaiero David G — Chief Financial Officer | Option exercise (M): 3,239 @ $1.68 · Option exercise (M): 4,746 @ $1.69 · Option exercise (M): 2,373 @ $1.69 · Option exercise (M): 3,239 (derivative) @ $0 · Option exercise (M): 4,746 (derivative) @ $0 · Option exercise (M): 2,373 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | RENSCHLER MARKUS MD — President and CEO, Director | Option exercise (M): 12,607 @ $1.69 · Option exercise (M): 2,537 @ $1.20 · Option exercise (M): 6,304 @ $1.69 · Option exercise (M): 12,607 (derivative) @ $0 · Option exercise (M): 2,537 (derivative) @ $0 · Option exercise (M): 6,304 (derivative) @ $0 | EDGAR |
| 2024-02-16 | 4 | George Jean — Director | Option exercise (M): 14,150 @ $1.69 · Option exercise (M): 14,150 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Sands Stephen H. — Director | Option exercise (M): 12,129 @ $1.69 · Option exercise (M): 12,129 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | THERO JOHN F — Director | Option exercise (M): 12,828 @ $1.69 · Option exercise (M): 12,828 (derivative) @ $0 | EDGAR |
| 2024-02-08 | 4 | Zakrzewski Joseph S — Director | Option exercise (M): 14,150 @ $1.69 · Option exercise (M): 14,150 (derivative) @ $0 | EDGAR |
| 2023-12-14 | 4 | Gaiero David G — Chief Financial Officer | Option exercise (M): 1,620 @ $1.68 · Option exercise (M): 2,373 @ $1.69 · Option exercise (M): 1,620 (derivative) @ $0 · Option exercise (M): 2,373 (derivative) @ $0 | EDGAR |
| 2023-12-14 | 4 | RENSCHLER MARKUS MD — President and CEO, Director | Option exercise (M): 6,304 @ $1.69 · Option exercise (M): 2,536 @ $1.20 · Option exercise (M): 6,304 (derivative) @ $0 · Option exercise (M): 2,536 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4 | Gaiero David G — Chief Financial Officer | Option exercise (M): 52,584 @ $1.68 · Option exercise (M): 21,356 @ $1.69 · Option exercise (M): 52,584 (derivative) @ $0 · Option exercise (M): 21,356 (derivative) @ $0 | EDGAR |
| 2023-11-22 | 4 | RENSCHLER MARKUS MD — President and CEO, Director | Option exercise (M): 56,737 @ $1.69 · Option exercise (M): 27,900 @ $1.20 · Option exercise (M): 56,737 (derivative) @ $0 · Option exercise (M): 27,900 (derivative) @ $0 | EDGAR |
| 2023-07-20 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 1,900 @ $2.76 · Sale (S): 100,000 @ $2.75 | EDGAR |
| 2023-07-18 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 11,000 @ $2.74 · Sale (S): 21,100 @ $2.75 · Sale (S): 6,500 @ $2.76 | EDGAR |
| 2023-07-03 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 200,937 @ $2.63 | EDGAR |
| 2023-06-28 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 8,437 @ $1.79 · Sale (S): 31,978 @ $1.77 | EDGAR |
| 2023-06-23 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 4,834 @ $1.99 · Sale (S): 5,041 @ $1.94 · Sale (S): 3,423 @ $1.88 | EDGAR |
| 2023-06-20 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 10,002 @ $2.03 · Sale (S): 5,983 @ $2.03 · Sale (S): 744 @ $2.11 | EDGAR |
| 2023-06-14 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 900 @ $2.06 · Sale (S): 2,626 @ $2.10 · Sale (S): 2,872 @ $2.11 | EDGAR |
| 2023-02-07 | 4 | Sands Stephen H. — Director | Grant/award (A): 12,129 (derivative) @ $0 | EDGAR |
| 2023-02-07 | 4 | Romberger Timothy — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2023-02-07 | 4 | Humphrey Jeffrey — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2023-02-07 | 4 | Bracken Racquel — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2023-02-07 | 4 | Gaiero David G — Chief Financial Officer | Grant/award (A): 5,000 @ $1.49 · Grant/award (A): 113,900 (derivative) @ $0 | EDGAR |
| 2023-02-07 | 4 | Gaiero David G — Chief Financial Officer | Option exercise (M): 4,100 @ $1.68 · Option exercise (M): 4,100 (derivative) @ $0 | EDGAR |
| 2023-02-07 | 4 | Veness Adam M — General Counsel | Grant/award (A): 96,100 (derivative) @ $0 | EDGAR |
| 2023-02-07 | 4 | Molineaux Susan — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2023-02-07 | 4 | Zakrzewski Joseph S — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2023-02-07 | 4 | George Jean — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2023-02-07 | 4 | RENSCHLER MARKUS MD — President and CEO, Director | Grant/award (A): 5,000 @ $1.49 · Grant/award (A): 302,600 (derivative) @ $0 | EDGAR |
| 2023-02-07 | 4 | THERO JOHN F — Director | Grant/award (A): 12,828 (derivative) @ $0 | EDGAR |
| 2022-12-23 | 4 | RENSCHLER MARKUS MD — President and CEO, Director | Option exercise (M): 106,345 @ $1.03 · Option exercise (M): 30,437 @ $1.20 · Option exercise (M): 106,345 (derivative) @ $0 · Option exercise (M): 30,437 (derivative) @ $0 | EDGAR |
| 2022-12-08 | 4 | Zakrzewski Joseph S — Director | Purchase (P): 21,202 @ $1.30 | EDGAR |
| 2022-12-08 | 4/A | Zakrzewski Joseph S — Director | Holdings only — no transactions reported | EDGAR |
| 2022-07-22 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 900,000 @ $3 | EDGAR |
| 2022-05-16 | 4 | Zakrzewski Joseph S — Director | Purchase (P): 743 @ $1.61 | EDGAR |
| 2022-05-12 | 4 | Zakrzewski Joseph S — Director | Purchase (P): 49,406 @ $1.89 · Purchase (P): 1,000 @ $1.70 | EDGAR |
| 2022-05-12 | 4 | THERO JOHN F — Director | Purchase (P): 10,000 @ $2 | EDGAR |
| 2022-05-04 | 4 | Veness Adam M — General Counsel | Grant/award (A): 177,000 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | Bracken Racquel — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | Romberger Timothy — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | Naesens Janwillem — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | Secrist John Paul — Chief Scientific Officer | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | Gaiero David G — Vice President, Finance | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | Sands Stephen H. — Director | Grant/award (A): 28,300 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | Gengos Andrew — Chief Business Officer | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | Molineaux Susan — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | Zakrzewski Joseph S — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | George Jean — Director | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2022-02-24 | 4 | RENSCHLER MARKUS MD — President and CEO, Director | Grant/award (A): 106,200 (derivative) @ $0 | EDGAR |
Recent 8-K events — Cyteir Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-03-20 | 8-K | 1.02 — Termination of a Material Definitive Agreement 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-03-07 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-12-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-12-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-12-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-11-17 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2023-10-12 | 8-K | 8.01 — Other Events | EDGAR |
| 2023-10-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2023-06-30 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-14 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CYT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs